ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 556

Identification and Validation of S100 Salivary Proteins As Putative Biomarkers for Different  Subsets of Primary Sjögren’s Syndrome Patients

Chiara Baldini1, Francesco Ferro2, Nadia Ucciferri3, Enza Polizzi2, Silvia Rocchiccioli3, Marta Mosca2 and Antonella Cecchettini3, 1Internal Medicine, Rheumatology Unit, University of Pisa, Pisa, Italy, 2Rheumatology Unit, University of Pisa, Pisa, Italy, 3IFC, CNR, Pisa, Italy

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: proteomics and salivary hypofunction, Sjogren's syndrome

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 5, 2017

Title: Sjögren's Syndrome Poster I: Translational Research

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: S100 A proteins are multifunctional proteins expressed predominantly by myeloid cells, with a regulatory role in a variety of cellular processes including inflammation. Recently, serum and salivary S100A proteins have been described as increased in patients with primary Sjögren’s syndrome (pSS) with respect to healthy volunteers. In this study, we aimed at investigating whether salivary expression of S100 proteins may reflect different pSS disease phenotypes stratified on the basis of the complexity of minor salivary gland biopsies (MSGB) and on the impairment of unstimulated salivary flow rate (USFR).

Methods: Patients with pSS (AECG 2002) were included in this study at the diagnosis of the disease. Demographic and clinical data were collected prospectively as well as their USFR and MSGBs. A focus score (FS) ≥3 was considered as high and an USFR<2.5 ml/15’ was considered as low. Saliva samples were collected on ice, centrifuged and stored at -80°C. After removal of Albumin and IgG, a nano-HPLC system coupled with a Triple TOFTM 5600 mass spectrometer was used for the analysis of saliva proteomes of pSS patients. For the validation phase of the study, S100A7/psoriasin levels were determined by CircuLex S100A7/psoriasin ELISA kit (MBL International Corporation), according to manufacturer’s instructions.

Results: Fifteen pSS women were enrolled for the proteomic analysis: 5 with high FS and normal USFR, 5 with high FS and reduced USFR and 5 with low FS and reduced USFR. Among differentially expressed proteins, we found that S100 A2, 7, 8,9, 11 and 12 were significantly over-expressed in pSS with respect to controls. In details, S100 A7 levels were significantly increased in patients with higher FS and lower USFR with respect to the other two groups of patients; S100 A8 and A9 were increased in patients with higher FS and lower USFR only with respect to patients with high FS and normal USFR and S100 A 12 in patients with low FS and reduced USFR with respect to patients with high FS and normal USFR. We validated salivary expression of S100 A7 in 19 additional pSS patients and 8 controls confirming that S100A7 expression was significantly higher in patients with high FS and reduced USFR (305.6± 174 ng/ml vs 11±14 ng/ml vs 75.7±21.6 ng/ml, p=0.000).

Conclusion: Salivary S100 A proteins appeared as interesting novel potential biomarkers for the non-invasive stratification of homogenous subgroups of patients with pSS. ELISA results excellently mirrored proteomics and open the possibility to be clinically translated into routine diagnostic.


Disclosure: C. Baldini, None; F. Ferro, None; N. Ucciferri, None; E. Polizzi, None; S. Rocchiccioli, None; M. Mosca, None; A. Cecchettini, None.

To cite this abstract in AMA style:

Baldini C, Ferro F, Ucciferri N, Polizzi E, Rocchiccioli S, Mosca M, Cecchettini A. Identification and Validation of S100 Salivary Proteins As Putative Biomarkers for Different  Subsets of Primary Sjögren’s Syndrome Patients [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/identification-and-validation-of-s100-salivary-proteins-as-putative-biomarkers-for-different-subsets-of-primary-sjogrens-syndrome-patients/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/identification-and-validation-of-s100-salivary-proteins-as-putative-biomarkers-for-different-subsets-of-primary-sjogrens-syndrome-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology